Bringing Clinical Trials to Life


Like our clients, we are committed to the quest to cure cancer. But cancer is not just a single disease. It takes deep trial knowledge to know how to address its many forms. Learn how Synteract has stayed ahead of the trends…More...

Neuro Degenerative

Neuro degenerative disorders are some of the most confounding and complex to affect people. Our specialized experience in these trials aids you in developing treatments that improve functioning and help the lives of both patients and caregivers…More...

Rare & Orphan Disease

Rare and orphan diseases have unique characteristics, not the least of which is finding the right population for your trials. We know the investigators and study sites that can help to address your recruitment goals, among other challenges…More...


Pediatric trials run the gamut of indications in drug development, but they all have primary things in common – working with children and their families requires specialized expertise and deep knowledge of regulatory requirements….More...

5/9/2018 - 5/10/2018 : Clinical Leader Forum More...

4/19/2018: Synteract, an innovative contract research organization (CRO) providing full-service, Phase I-IV services to biopharma companies bringing new medicines to market, has enhanced its focus. More ...

4/19/2018: The Beginning of a New Era - We are excited to announce that after thoughtful evaluation of our areas of notable experience and customer and market demand, we have enhanced our focus. Synteract Blog 

4/24/2018: Learn more about our creation of therapeutic centers of development in our latest blog post. These areas include some of the most progressive in the biopharma industry: oncology, especially leading-edge immunotherapy studies, neuro-degenerative disorders, pediatrics, and rare and orphan disease.
Synteract on LinkedIn

4/19/2018: RT @OutsourcPharma: .@Synteract focusing on specific therapeutic areas as it eyes market growth
Synteract Twitter Feed


Contact Synteract

Tell us how to stay in touch with you: